In the phase 1 clinical trial NCT03219268, the efficacy of anti-LAG-3 × PD-1 BsAb Tebotelimab was explored in patients with solid tumors or hematologic malignancies [132]. The gene discussed is LAG3; the disease is hematologic disorder.